CAS 1884461-72-6

Ensifentrine

CAS: 1884461-72-6

Formula: C₂₆H₃₁N₅O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 477.5554

Ref: IN-DA01V7CR

Ensifentrine

CAS: 1884461-72-6

(E)-1-(2-(2-(Mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea

Formula: C₂₆H₃₁N₅O₄

Purity: 98+%

Molecular weight: 477.56

Ref: IN-DG01492811

Ensifentrine

CAS: 1884461-72-6

Ensifentrine

Formula: C₂₆H₃₁N₅O₄

Purity: ≥98%

Molecular weight: 477.56

Ref: 54-BUP07823

Ensifentrine

CAS: 1884461-72-6

Formula: C₂₆H₃₁N₅O₄

Molecular weight: 477.57

Ref: 4Z-E-225001

Ensifentrine

CAS: 1884461-72-6

Ensifentrine (Ensifentrinum) is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that

Formula: C₂₆H₃₁N₅O₄

Purity: 99.76% - 99.94%

Color and Shape: Green Solid

Molecular weight: 477.56

Ref: TM-T25376

Ensifentrine

CAS: 1884461-72-6

Formula: C₂₆H₃₁N₅O₄

Molecular weight: 477.56

Ref: ST-EA-CP-E78000

RPL 554

Controlled Product

CAS: 1884461-72-6

Formula: C₂₆H₃₁N₅O₄

Color and Shape: Neat

Molecular weight: 477.555

Ref: TR-R700940

Ensifentrine

CAS: 1884461-72-6

Ensifentrine is an orally active, long-acting bronchodilator. It is a phosphodiesterase inhibitor that relaxes the smooth muscle in the airways and reduces the inflammation of the bronchial tubes. Ensifentrine has been shown to be effective in patients with chronic bronchitis and oesophageal varices. Ensifentrine is administered by inhalation as a nebulized solution. The recommended dose for adults with chronic bronchitis is 20 mg twice daily for 4 weeks, followed by 20 mg once daily for 8 weeks. The recommended dose for patients with oesophageal varices is 40 mg twice daily for 4 weeks, followed by 40 mg once daily for 8 weeks. Ensifentrine has not been studied in children less than 18 years old or pregnant women.

Formula: C₂₆H₃₁N₅O₄

Purity: Min. 95%

Molecular weight: 477.6 g/mol

Ref: 3D-JAD46172